NR1H4 and primary biliary cholangitis: OCA as an FXR agonist has a pluripotent mode of action in PBC, regulating bile-acid conjugation and its transport, reducing liver inflammation (as shown by liver enzymes), and, finally, diminishing fibrosis (as demonstrated by TE and LiMAx analyses in a short-term clinical course).